# Source check — claim dc6da6aadacc0f4ec8c8e4c6ec951f212a4da2abc0f2aac4d509805ec0335e27

Claim: Abstract extract PMID 42586176 ("Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2+ breast cancer."):  Key fragments: Trastuzumab resistance remains a major clinical barrier in the treatment of HER2-positive breast cancer. To identify thera | peutic candidates capable of overcoming resistance, we established trastuzumab-resistant derivatives of SKBR3 and BT474 cells and performed a high-thr | e to myricetin, confirming that its cytotoxicity is at least partly mitochondria-dependent. In vivo, myricetin significantly inhibited the growth of Abstract-only SHA-256 TITLE+PMID+ABSTRACT=3510d6520d6a89fe92073413a5620503378881bf6877366d9d029187a795d42c. Not treatment advice.
Source: PMID 42586176 (https://pubmed.ncbi.nlm.nih.gov/42586176/)
Checked: 2026-09-23T15:41:44.582Z

## Method
1. Fetched abstract via NCBI efetch (rettype=abstract).
2. Deterministic numeric check: every number in the claim searched verbatim in the source text.
3. Semantic check: qwen3:8b (temp 0), schema-constrained verdict.

## Findings
Numeric tokens missing from source: 256, 3510, 6520, 89, 92073413, 5620503378881, 6877366, 029187, 795
Model verdict: supports
Reasoning: The source text supports the claim. The text states that myricetin was identified as a top hit with selective anti-survival activity against trastuzumab-resistant cells. It also describes mitochondrial mechanisms of myricetin's cytotoxicity and reports in vivo efficacy in inhibiting tumor growth. These findings align with the claim that myricetin is a therapeutic candidate capable of overcoming trastuzumab resistance in HER2+ breast cancer.
Final result: inconclusive (confidence 4000 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: 7d6efa41a937be93901019396d266e37d5f0f991e5f15d252d82c2239805b96a